Circulation reports最新文献

{"title":"Anti-Oxidized Low-Density Lipoprotein Antibodies Before and After Intravenous Immunoglobulin Therapy in Kawasaki Disease　- Evidence for a Potentially Protective Role.","authors":"Zenpei Kano, Yumi Mizuno, Kenji Murata, Sagano Onoyama, Takayuki Hoshina, Yasunari Sakai, Junji Kishimoto, Koichi Kusuhara, Toshiro Hara","doi":"10.1253/circrep.CR-25-0018","DOIUrl":"https://doi.org/10.1253/circrep.CR-25-0018","url":null,"abstract":"<p><strong>Background: </strong>The precise pathogenesis of Kawasaki disease (KD) remains unclear, but immune dysregulation involving damage-associated molecular patterns (DAMPs), such as oxidized low-density lipoprotein (LDL) and high mobility group box 1 (HMGB1), has been implicated. We investigated the roles of 2 anti-DAMPs antibodies in KD and their associations with inflammatory and oxidative stress markers.</p><p><strong>Methods and results: </strong>Serum levels of anti-oxidized LDL and anti-HMGB1 antibodies were measured by enzyme-linked immunosorbent assay in patients with KD and in febrile disease controls (DC). Correlations with inflammatory (C-reactive protein [CRP]) and oxidative stress (red blood cell distribution width [RDW]) markers were evaluated. Serum anti-oxidized LDL antibody levels increased significantly after intravenous immunoglobulin (IVIG) therapy in KD patients, suggesting a protective role of anti-oxidized LDL antibodies against vascular inflammation. Conversely, anti-HMGB1 antibody levels showed a decreasing trend post-IVIG. A significant correlation between antibody levels and CRP was observed in DC but not in KD patients. Furthermore, a weak inverse trend between anti-oxidized LDL antibodies and RDW-coefficient of variation was noted in KD patients.</p><p><strong>Conclusions: </strong>This study highlighted the distinct roles of anti-oxidized LDL and anti-HMGB1 antibodies during the acute phase of KD. The increase in anti-oxidized LDL antibodies following IVIG treatment suggests a protective effect, while the transient nature of anti-HMGB1 antibodies warrants further exploration.</p>","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 5","pages":"359-364"},"PeriodicalIF":0.0,"publicationDate":"2025-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12061508/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144047131","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reducing the Burden of Heart Failure in Japan With Dapagliflozin　- A Cost Offset Model (IMPLICATION HF).","authors":"Takuya Kishi, Eriko Kunikane, Hiroyuki Takagi, Jieling Chen, Luis Varela, Asuka Ozaki","doi":"10.1253/circrep.CR-25-0022","DOIUrl":"10.1253/circrep.CR-25-0022","url":null,"abstract":"<p><strong>Background: </strong>Dapagliflozin is clinically beneficial in heart failure (HF). However, how these clinical benefits translate into economic burden reduction is unclear. With IMPLICATION HF, we projected the reductions in HF events and costs that would result from dapagliflozin use in Japan using a cost offset model.</p><p><strong>Methods and results: </strong>The modeled population comprised symptomatic HF patients from the DAPA-HF and DELIVER trials. We compared the event incidences and associated costs between HF treatment with and without dapagliflozin, using the prevalence, event rates, and event costs of HF in Japan from published literature, as well as the treatment effects of dapagliflozin from the pooled meta-analysis of DAPA-HF and DELIVER. The cumulative number of events (HF hospitalization [hHF], cardiovascular [CV] death, and all-cause death) and associated costs (hHF, CV death, total) were projected. Cost offsets were calculated according to the difference in event-related costs between HF treatment with and without dapagliflozin. Dapagliflozin was estimated to prevent 63,770 hHF events (number needed to treat [NNT] 20), 11,613 CV deaths (NNT 108), and 16,141 all-cause deaths (NNT 78), as well as reducing hHF and CV death costs by JPY62.7 billion and JPY16.6 billion, totaling JPY79.3 billion over 1 year in Japan. The sensitivity analyses corroborated these findings.</p><p><strong>Conclusions: </strong>The addition of dapagliflozin to HF treatment is projected to provide economic benefits to the Japanese healthcare system.</p>","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 6","pages":"426-432"},"PeriodicalIF":0.0,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12148354/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144268335","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Rationale and Design of an Exploratory, Randomized, Open-Label, Multicenter Clinical Trial to Investigate the Efficacy of Long-Acting β2-Agonist/Long-Acting Muscarinic Antagonist on Heart Failure Complicated by Chronic Obstructive Pulmonary Disease (COPD-HF Trial).","authors":"Hiroya Hayashi, Shin Ito, Hiroki Fukuda, Makoto Sata, Yukio Abe, Kohei Fujimoto, Daiju Fukuda, Yohei Hanajima, Mutsuo Horii, Noriyuki Ikehara, Moriaki Inoko, Chisato Izumi, Yasuhiro Izumiya, Takafumi Nakayama, Takashi Sozu, Shigeru Toyoda, Masafumi Watanabe, Masashi Yokoi, Masafumi Kitakaze","doi":"10.1253/circrep.CR-25-0010","DOIUrl":"https://doi.org/10.1253/circrep.CR-25-0010","url":null,"abstract":"<p><strong>Background: </strong>Chronic obstructive pulmonary disease (COPD) is one of the most common comorbidities in patients with chronic heart failure (CHF). A growing number of patients are suffering from both COPD and CHF, and these conditions worsen each other. Inhaled bronchodilator therapy with long-acting muscarinic antagonist (LAMA) and long-acting β2-agonist (LABA) in combination is currently the mainstay of treatment for COPD. However, the effect of LAMA/LABA on HF with COPD remains unknown.</p><p><strong>Methods and results: </strong>The COPD-HF trial is a multicenter, double-arm, open-label, exploratory, investigator-initiated clinical study to investigate the effect of LAMA/LABA on HF in patients suffering from both COPD and CHF. The participants are randomly assigned (1 : 1) to the LAMA/LABA (tiotropium+olodaterol FDC (fixed-dose combination) 5/5 ug) group (once a day, 2 inhalations) or non-pharmacological treatments for COPD as a control group. The planned number of patients to be enrolled in this trial is 54 in total (27 in each group). The participants are followed up for 12 weeks with and without LAMA/LABA. The primary endpoint is the change in plasma B-type natriuretic peptide levels from the baseline to the end of this study (12 weeks).</p><p><strong>Conclusions: </strong>The COPD-HF trial will investigate the efficacy of LAMA/LABA on HF in patients with COPD and CHF.</p>","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 5","pages":"383-388"},"PeriodicalIF":0.0,"publicationDate":"2025-04-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12061507/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056750","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Use of Electron Density Maps and Fused Images in Dual-Energy Cardiac Computed Tomography to Facilitate Detection of Late Iodine Enhancement.","authors":"Junji Mochizuki, Yoshiki Hata, Takeshi Nakaura, Yasunori Nagayama, Masafumi Kidoh, Hiroyuki Uetani, Kaori Shiraishi, Naoki Kobayashi, Yoshinori Funama, Toshinori Hirai","doi":"10.1253/circrep.CR-24-0115","DOIUrl":"https://doi.org/10.1253/circrep.CR-24-0115","url":null,"abstract":"<p><strong>Background: </strong>This study aimed to optimize the fusion of quantitative maps and morphological images to improve late iodine enhancement (LIE) imaging using cardiac dual-energy computed tomography (DECT).</p><p><strong>Methods and results: </strong>We retrospectively analyzed 15 patients with suspected old myocardial infarction who underwent cardiac DECT. Virtual monochromatic images (VMI) ranging from 40 to 200 keV and quantitative maps (e.g., iodine concentration, effective atomic number, and electron density [(%EDW: percentage relative to the electron density of water)] were generated. The contrast-to-noise ratio (CNR) between LIE areas and the left ventricular (LV) blood pool and normal myocardium was calculated to determine the optimal image fusion for LIE delineation. VMI at 40 keV demonstrated superior CNR between LIE areas and normal myocardium. Electron density was significantly higher in LIE areas [105.5%EDW (interquartile range (IQR): 105.15-105.65)] than in the LV blood pool [104.4%EDW (IQR: 104.3-104.6)] and normal myocardium [104.4%EDW (IQR: 104.2-104.65)] (P<0.001). Iodine concentration and effective atomic number differed significantly between LIE areas and normal myocardium, but did not differ significantly between LIE areas and the LV blood pool. Fusion of 40 keV VMI with electron density maps yielded the highest area under the receiver operating characteristic curve (0.917).</p><p><strong>Conclusions: </strong>Fused images combining 40 keV VMI with electron density maps significantly enhanced the visualization of LIE areas on DECT, offering improved contrast and diagnostic accuracy for the assessment of myocardial territories.</p>","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 5","pages":"341-349"},"PeriodicalIF":0.0,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12061510/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144014064","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effects of Transcutaneous Auricular Vagus Nerve Stimulation on Hemodynamics and Autonomic Function During Exercise Stress Tests in Healthy Volunteers.","authors":"Yosuke Yoshida, Satoshi Okayama, Daisuke Fujihara, Midori Taniyama, Ayami Yamada, Megumi Fukui, Naoki Doi, Runa Takahashi, Akihiro Tanabe, Shingo Ogaki, Satoharu Hattori, Atsushi Iwai, Michitaka Nakamura, Naofumi Doi, Yoshihiko Saito","doi":"10.1253/circrep.CR-24-0136","DOIUrl":"https://doi.org/10.1253/circrep.CR-24-0136","url":null,"abstract":"<p><strong>Background: </strong>Transcutaneous auricular vagus nerve stimulation (taVNS) is a potential treatment for cardiovascular disease, but data on its effects on physiological function during exercise are lacking. We investigated the effects of taVNS on hemodynamics and autonomic nervous system function during exercise stress tests.</p><p><strong>Methods and results: </strong>Sixteen healthy volunteers underwent exercise stress tests with and without taVNS in this study, with a randomized crossover design and with a washout period of at least 7 days. taVNS was set to a frequency of 100 Hz and maximum current intensity without causing discomfort. Hemodynamics and autonomic nervous system function were evaluated using plethysmography and heart rate (HR) variability, respectively. After exclusion of an outlier, data of 15 participants were analyzed. In tests with taVNS, HR was significantly reduced at maximum exercise (136.0±9.7 vs. 132.0±9.2; P<0.001) and 1 min after exercise (115.0±11.4 vs. 104.0±15.0; P<0.001), with minimal changes in blood pressure. The stroke volume and total peripheral resistance at maximum exercise significantly increased and decreased, respectively. Furthermore, low/high frequency ratio reflecting sympathetic dominance decreased at rest (3.7±2.5 vs. 1.6±1.3; P<0.001) and at maximum exercise (4.5±4.5 vs. 1.2±0.9; P<0.001).</p><p><strong>Conclusions: </strong>taVNS can reduce HR with minimal effect on blood pressure by inducing parasympathetic dominance during exercise stress tests.</p>","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 5","pages":"315-322"},"PeriodicalIF":0.0,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12061502/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144053653","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"One-Week Postoperative Valvuloarterial Impedance as a Predictor of Left Ventricular Hypertrophy Regression 1 Year After Surgical Aortic Valve Replacement in Patients With Aortic Stenosis.","authors":"Hirotaka Waki, Kenji Harada, Yusuke Suzuki, Yutaka Aoyama, Masafumi Sato, Sumika Wachi, Yusuke Ishiyama, Yukiyo Ogata, Koji Kawahito, Kazuomi Kario","doi":"10.1253/circrep.CR-24-0158","DOIUrl":"10.1253/circrep.CR-24-0158","url":null,"abstract":"<p><strong>Background: </strong>Persistent left ventricular hypertrophy (LVH) after surgical aortic valve replacement (SAVR) for aortic stenosis (AS) worsens prognosis. We investigated predictors of LVH regression 1 year after SAVR in AS patients, including patient-prosthesis mismatch (PPM) and valvuloarterial impedance (Zva).</p><p><strong>Methods and results: </strong>We retrospectively studied 175 patients who underwent SAVR for AS at Jichi Medical University between 2014 and 2019. Echocardiography was performed at preoperative baseline, 1-week postoperative, and 1-year postoperative. The left ventricular mass index (LVMI) regression rate (RR) was defined as the difference between baseline LVMI and 1-year LVMI divided by baseline LVMI. Patients were divided into 2 groups based on their median LVMI RR as follows: (1) a poor LVH regression (PR-LVH) group with values below the median LVMI RR; and (2) a good LVH regression (GR-LVH) group with values above the median LVMI RR. The median LVMI RR was 25.4%. There were 88 (50.3%) patients in the PR-LVH group. In the multivariable analysis, 1-week postoperative Zva (odds ratio [OR] 2.777; 95% confidence interval [CI] 1.584-4.869; P<0.001) and baseline LVMI per 10-unit increment (OR 0.974; 95% CI 0.960-0.988; P=0.001) were independent predictors of PR-LVH. The receiver operating characteristic curve analysis identified Zva ≥3.5 mmHg/mL/m² as a cut-off value associated with PR-LVH.</p><p><strong>Conclusions: </strong>One-week postoperative Zva was a better predictor of improved LVH at 1 year after SAVR than PPM.</p>","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 6","pages":"473-480"},"PeriodicalIF":0.0,"publicationDate":"2025-04-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12148358/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144268331","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Population Gap for Chronic Heart Failure Patients Between Randomized Controlled Trials and Japan's Super-Aged Society.","authors":"Jun-Ichi Noiri, Wataru Fujimoto, Makoto Takemoto, Koji Kuroda, Soichiro Yamashita, Junichi Imanishi, Masamichi Iwasaki, Takafumi Todoroki, Masanori Okuda, Manabu Nagao, Akihide Konishi, Masakazu Shinohara, Ryuji Toh, Kunihiro Nishimura, Hidekazu Tanaka","doi":"10.1253/circrep.CR-25-0002","DOIUrl":"https://doi.org/10.1253/circrep.CR-25-0002","url":null,"abstract":"<p><strong>Background: </strong>Heart failure (HF) management has been improved by guideline-directed medical therapy (GDMT) based on findings of major randomized controlled trials (RCTs). However, the applicability of these findings to real-world HF populations, especially Japan's current super-aged society, remains uncertain.</p><p><strong>Methods and results: </strong>We analyzed findings for chronic HF patients from the KUNIUMI registry, a prospective observational study conducted on Awaji Island, Japan, representative of a super-aged society (aging rate ≈37%). We determined what percentage of these patients met the inclusion criteria as well as the exclusion criteria of 6 major representative RCTs (PARADIGM-HF, PARAGON-HF, DAPA-HF, DELIVER, EMPEROR-Reduced, EMPEROR-Preserved) and compared the incidence of cardiovascular death and HF hospitalization over 3 years for patients who did and did not meet the exclusion criteria. Of the 1,646 patients from the KUNIUMI registry, 225 were eligible for PARADIGM-HF, DAPA-HF and EMPEROR-Reduced, 554 for PARAGON-HF, and 631 for DELIVER and EMPEROR-Preserved. The exclusion percentages for the overall eligible population were 48.4% (PARADIGM-HF), 36.4% (DAPA-HF), 42.7% (EMPEROR-Reduced), 57.9% (PARAGON-HF), 32.3% (DELIVER), and 31.4% (EMPEROR-Preserved). It should be noted that ineligible patients had a poorer prognosis than eligible patients (P<0.05 for each trial).</p><p><strong>Conclusions: </strong>The population gap between HF patients in major RCTs and the current super-aged society underscores the need for further evidence of GDMT in real-world settings.</p>","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 5","pages":"331-340"},"PeriodicalIF":0.0,"publicationDate":"2025-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12061505/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056939","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Neutrophil Extracellular Traps Capturing SARS-CoV-2 in the Lung Tissue (Alveoli and Parenchyma) Cause Microthrombi　- A Strategy to Eliminate SARS-CoV-2 From the Circulation as Degraded Fibrin Clots.","authors":"Hiroshi Katayama","doi":"10.1253/circrep.CR-24-0157","DOIUrl":"https://doi.org/10.1253/circrep.CR-24-0157","url":null,"abstract":"<p><strong>Background: </strong>It has been thought that neutrophil extracellular traps (NETs) and thrombosis exacerbate COVID-19, but, on the other hand, NETs are an important player in innate immunity. The precise roles of NETs and thrombosis in the course of COVID-19 have not been fully elucidated.</p><p><strong>Methods and results: </strong>The roles were investigated in the literature and a new theory was formulated. When neutrophils encounter SARS-CoV-2 in the lung tissue, they undergo NETosis and capture the virus. This capture is triggered by electrostatic interaction between histones in NETs and SARS-CoV-2; histones are highly positively charged, and viruses, including SARS-CoV-2, have a net negative charge under physiological pH. NETs that capture SARS-CoV-2 fall into alveolar capillaries through the collapsed endothelium to spare the lung tissue from the toxicity of NETs. NETs in the microvessels cause microthrombosis; positively charged histones induce the aggregation of negatively charged platelets, which leads to microthrombi. Microthrombi engulfing SARS-CoV-2 are consolidated into fibrin clots, which are eventually degraded by increased fibrinolysis and eliminated from the circulation.</p><p><strong>Conclusions: </strong>This novel theory suggests that NETosis and microthrombosis are phenomena inevitably elicited in COVID-19, and in combination they are a system newly termed \"NETombosis\". Undegraded fibrin clots remaining in the microcirculation may be the cause of the sequelae, because they cause long-lasting circulatory failure in various organs.</p>","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 5","pages":"379-382"},"PeriodicalIF":0.0,"publicationDate":"2025-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12061506/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056330","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) Is an Independent Risk Factor for the Development of Ischemic Heart Disease　- A 10-Year Cohort Study.","authors":"Toshifumi Ogawa, Tatsuya Sato, Marenao Tanaka, Yukinori Akiyama, Kei Nakata, Hidemichi Kouzu, Kazuma Mori, Hiroki Aida, Wataru Kawaharata, Itaru Hosaka, Toru Suzuki, Nagisa Hanawa, Masato Furuhashi","doi":"10.1253/circrep.CR-25-0019","DOIUrl":"https://doi.org/10.1253/circrep.CR-25-0019","url":null,"abstract":"<p><strong>Background: </strong>The association of each of the recently classified steatotic liver diseases (SLDs), including metabolic dysfunction-associated SLD (MASLD), MASLD and increased alcohol intake (MetALD), and alcohol-associated liver disease (ALD), with new development of ischemic heart disease (IHD) remains unclear.</p><p><strong>Methods and results: </strong>We investigated the associations of various SLDs with the development of IHD during a 10-year follow-up period in 13,815 Japanese individuals without a history of IHD (men/women 8,933/4,882; mean age 48 years) who underwent annual health checkups including an abdominal ultrasound examination. Among the participants, 4,639 (33.6%) subjects were diagnosed as having SLDs, and the proportions of subjects with MASLD, MetALD and ALD were 25.4%, 4.7% and 1.9%, respectively. During the follow-up period, 1,963 (16.2%; men/women 1,374 [17.2%]/589 [14.2%]) subjects had new development of IHD. Multivariable Cox proportional hazard model analysis after adjustment of age, sex, estimated glomerular filtration rate (eGFR), current smoking habit, diabetes, hypertension and dyslipidemia showed that the adjusted risk for new onset of IHD was significantly higher in subjects with MASLD (hazard ratio 1.20 [95% confidence interval 1.01-1.55]; P=0.042) than in those without SLD. Other SLDs were not selected as independent risk factors for the development of IHD.</p><p><strong>Conclusions: </strong>The presence of MASLD, but not other SLDs, is an independent risk factor for new onset of IHD during a 10-year follow-up period.</p>","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 5","pages":"350-358"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12061509/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144056326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Effect of Intensified Multifactorial Treatments on Coronary Atherosclerosis in Patients With Coronary Artery Disease and Type 2 Diabetes Mellitus　- Rationale and Design of the Randomized IMPACT-DM Trial.","authors":"Kozo Okada, Shinnosuke Kikuchi, Nobuhiko Maejima, Noriyuki Kawaura, Sho Kodama, Naoki Nakayama, Kenichiro Saka, Shunsuke Kataoka, Hiroyuki Suzuki, Hiroyuki Ishikawa, Shotaro Kuji, Yuki Saigusa, Chika Kawashima, Hidekuni Kirigaya, Yohei Hanajima, Hidefumi Nakahashi, Masaomi Gohbara, Jun Okuda, Kengo Tsukahara, Kazuki Fukui, Tsutomu Endo, Teruyasu Sugano, Kiyoshi Hibi","doi":"10.1253/circrep.CR-25-0021","DOIUrl":"10.1253/circrep.CR-25-0021","url":null,"abstract":"<p><strong>Background: </strong>The effect of Intensified Multifactorial treatments on coronary atherosclerosis in PAtients with Coronary artery disease and Type 2 Diabetes Mellitus (IMPACT-DM) trial was designed to investigate the effects of intensified multifactorial treatments (IMT) on coronary plaque progression in patients with coronary artery disease (CAD) and diabetes.</p><p><strong>Methods and results: </strong>In this prospective, randomized, open-label, parallel assignment, multicenter study, eligible patients with diabetes who underwent successful percutaneous coronary intervention in culprit lesions are randomly assigned to receive either IMT or guideline-oriented standard treatments (Control) for 18 months. The IMT are managed according to strict target goals and step-by-step medical treatment protocols based on modern medical treatments. Target goals in IMT and Control groups are set to hemoglobin A1c <6.2% vs. <7.0%; low-density lipoprotein cholesterol <55 mg/dL for any type of CAD vs. <70 mg/dL for acute coronary syndrome, or <100 mg/dL for stable CAD; and blood pressure <120/80 mmHg vs. <130/80 mmHg, respectively. Non-culprit lesions are evaluated using intravascular ultrasound (IVUS) at post-procedure and 18 months follow up. The primary endpoint is absolute changes in percent plaque volumes in non-culprit lesions as assessed using IVUS from post-procedure to 18 months.</p><p><strong>Conclusions: </strong>The IMPACT-DM trial will clarify the clinical benefits of IMT on non-culprit coronary plaques in patients with diabetes undergoing successful PCI in culprit lesions.</p>","PeriodicalId":94305,"journal":{"name":"Circulation reports","volume":"7 6","pages":"486-490"},"PeriodicalIF":0.0,"publicationDate":"2025-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12148355/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144268326","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}